Lundbeck’s alcohol pill hits speed bump
The Danish Health and Medicines Authority has turned down Lundbeck’s appeal for general reimbursement for its alcohol pill. The company says it will not impact sales, while an analyst points out that Lundbeck has work to do to convince medicines authorities across Europe.
by Stefan Singh Kailay
Danish patients set to receive treatment with Lundbeck’s pill against alcohol addiction, Selincro, will not automatically receive reimbursements for the drug.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Lundbeck launches alcohol pill in UK
For abonnenter
Lundbeck launches alcohol pill on first markets
For abonnenter
Alcohol pill delivers promising results
For abonnenter
